Amicus Therapeutics Recognized as a Great Place to Work® in Europe
April 28, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, April 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel...
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
April 26, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, April 26, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at...
Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference
March 15, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, March 15, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will...
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
March 01, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
2020 Total Galafold Revenue of $260.9M; Increased 43 Percent Year-on-Year Continued Strong Global Growth of Galafold Expected in 2021 with Revenue of $300M-$315M AT-GAA Rolling BLA...
Amicus Therapeutics to Present at Upcoming Investor Conferences
February 18, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the...
Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
February 17, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 1, 2021 at...
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
February 11, 2021 16:01 ET
|
Amicus Therapeutics, Inc.
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021 Patients switching to AT-GAA from the approved standard of...
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
February 08, 2021 14:30 ET
|
Amicus Therapeutics, Inc.
Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses Further Validates Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy...
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
February 08, 2021 14:30 ET
|
Amicus Therapeutics, Inc.
Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease Plan to Submit IND for Next Clinical Study in 2H2021 PHILADELPHIA, Feb. 08, 2021 (GLOBE...
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
January 21, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel...